Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019–2020

Published:2023-01 Issue:2 Volume:41 Page:333-353
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Moll Keran,Lufkin Bradley,Fingar Kathryn R.,Ke Zhou Cindy,Tworkoski Ellen,Shi Chianti,Hobbi Shayan,Hu Mao,Sheng Minya,McCarty Jillian,Shangguan Shanlai,Burrell Timothy,Chillarige Yoganand,Beers Jeff,Saunders-Hastings Patrick,Muthuri Stella,Edwards Kathryn,Black Steven,Kelman Jeff,Reich Christian,Amend Kandace L.,Djibo Djeneba Audrey,Beachler Daniel,Ogilvie Rachel P.,Secora Alex,McMahill-Walraven Cheryl N.,Seeger John D.,Lloyd Patricia,Thompson Deborah,Dimova Rositsa,MaCurdy Thomas,Obidi Joyce,Anderson Steve,Forshee Richard,Wong Hui-Lee,Shoaibi Azadeh

Funder

U.S. Department of Health and Human Services

U.S. Food and Drug Administration

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference32 articles.

1. World Health Organization. WHO Director-General's statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV). https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov); 30 January 2020 [accessed 28 March 2022].

2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/; last updated 23 June 2022 [accessed 23 June 2022].

3. COVID-19 Vaccine Tracker. United States of America, https://covid19.trackvaccines.org/country/united-states-of-america/; last updated 28 March 2022 [accessed 28 March 2022].

4. The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety;Black;Vaccine,2021

5. Council for International Organizations of Medical Sciences. CIOMS Cumulative Pharmacovigilance Glossary Version 1.0, https://cioms.ch/wp-content/uploads/2021/03/CIOMS-Cumulative-PV-Glossary-v1.0.pdf; 25 March 2021 [accessed 11 April 2022].

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Risk of Cardiovascular Adverse Events and Appendicitis After COVID-19 Diagnosis in Adults in the United States: Implications of the Start of Follow-Up;2024-09-06

2. Risk of Neurologic or Immune-Mediated Adverse Events After COVID-19 Diagnosis in the United States;2024-07-18

3. Background incidence rates of health outcomes of interest for COVID-19 vaccine safety monitoring in a US population: a claims database analysis;BMJ Open;2024-07

4. Current Approaches in Postapproval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published Literature;Clinical Therapeutics;2024-07

5. Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring in South Korea;Journal of Health Informatics and Statistics;2024-05-31